Three-drug–based combinations evaluated as induction, incorporating IMiDs or PIs, followed by HDT-ASCT
| Reference . | Regimen . | CR pretransplant . | ORR pretransplant . | CR posttransplant . | ORR posttransplant . |
|---|---|---|---|---|---|
| 6 | VTD vs TD (3 cycles) | 19 vs 5% (P < .0001) | 93 vs 79% (P < .0001) | 38 vs 23% (P = .0004) | 93 vs 84% (P = .0025) |
| 8 | VTD vs TD (4 cycles) | 13 vs 12 (P = NS) | 88 vs 81% (P = NS) | 31 vs 33% (P = NS) | 89 vs 86% (P = NS) |
| 7 | VTD vs TD vs VBMCP/VBAD/B (6 cycles) | 35 vs 14 vs 21%* | 85 vs 62 vs 75%† | 46 vs 24 vs 38%‡ | 77 vs 57 vs 73%‡ |
| 36 | PAD vs VAD (3 cycles) | 7 vs 2% (P < .001) | 78 vs 5 (P < .001) | 21 vs 9% (P < .001) | 88 vs 75 (P < .001) |
| 15§ | VTD vs VCD | 19 vs 7% | 93 vs 89% | NA | NA |
| 9 | VTD vs VCD (4 cycles) | 66.3 vs 56.2% (VGPR) (P = .05) | 92.3 vs 83.4% (P = .01) | NA | NA |
| 13 | VRD (3 cycles) | 23% | Not available | 42% | NA |
| 14 | VRD (3 cycles) | 46% (CR + VGPR) | Not available | 88% (CR + VGPR) | NA |
| 16 | KTD (4 cycles) | 18% | 94% | 31% | NA |
| 17 | KRd (4 cycles) | 16% | 73% (≥VGPR) | 27% | 90% (≥VGPR) |
| 18 | KRd (4 cycles) | 11% | 47% (≥VGPR) | 19% | 56% (≥VGPR) |
| 19 | IRd (4 cycles) | 11.9% | 38% (≥VGPR) | 18.9% | 70% (≥VGPR) |
| Reference . | Regimen . | CR pretransplant . | ORR pretransplant . | CR posttransplant . | ORR posttransplant . |
|---|---|---|---|---|---|
| 6 | VTD vs TD (3 cycles) | 19 vs 5% (P < .0001) | 93 vs 79% (P < .0001) | 38 vs 23% (P = .0004) | 93 vs 84% (P = .0025) |
| 8 | VTD vs TD (4 cycles) | 13 vs 12 (P = NS) | 88 vs 81% (P = NS) | 31 vs 33% (P = NS) | 89 vs 86% (P = NS) |
| 7 | VTD vs TD vs VBMCP/VBAD/B (6 cycles) | 35 vs 14 vs 21%* | 85 vs 62 vs 75%† | 46 vs 24 vs 38%‡ | 77 vs 57 vs 73%‡ |
| 36 | PAD vs VAD (3 cycles) | 7 vs 2% (P < .001) | 78 vs 5 (P < .001) | 21 vs 9% (P < .001) | 88 vs 75 (P < .001) |
| 15§ | VTD vs VCD | 19 vs 7% | 93 vs 89% | NA | NA |
| 9 | VTD vs VCD (4 cycles) | 66.3 vs 56.2% (VGPR) (P = .05) | 92.3 vs 83.4% (P = .01) | NA | NA |
| 13 | VRD (3 cycles) | 23% | Not available | 42% | NA |
| 14 | VRD (3 cycles) | 46% (CR + VGPR) | Not available | 88% (CR + VGPR) | NA |
| 16 | KTD (4 cycles) | 18% | 94% | 31% | NA |
| 17 | KRd (4 cycles) | 16% | 73% (≥VGPR) | 27% | 90% (≥VGPR) |
| 18 | KRd (4 cycles) | 11% | 47% (≥VGPR) | 19% | 56% (≥VGPR) |
| 19 | IRd (4 cycles) | 11.9% | 38% (≥VGPR) | 18.9% | 70% (≥VGPR) |
IRd, ixazomib, lenalidomide, and dexamethasone; KRd, carfilzomib, lenalidomide, and dexamethasone; KTD, carfilzomib, lenalidomide, and dexamethasone; NA, not available; NS, not significant; ORR, overall response rate; PAD, bortezomib, adriamycin, and dexamethasone; TD, thalidomide and dexamethasone; VBCMP/VBAD, vincristine, BCNU, cyclophosphamide, melphalan, prednisone, adriamycin, dexamethasone.
VTD vs TD, P = .0001; VTD vs VBMCP/VBAD/B, P = .01.
VTD vs TD, P = .0001; VTD vs VBMCP/VBAD/B, P = .06.
VTD vs TD, P = .0001; VTD vs VBMCP/VBAD/B, P = .01.
Matched-pair analysis.